Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Change in Acquisitions & Divestments (2024 - 2025)

Historic Change in Acquisitions & Divestments for TScan Therapeutics (TCRX) over the last 2 years, with Q3 2025 value amounting to $34.0 million.

  • TScan Therapeutics' Change in Acquisitions & Divestments fell 3928.57% to $34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $261.8 million, marking a year-over-year change of. This contributed to the annual value of $192.7 million for FY2024, which is 86328.5% up from last year.
  • Per TScan Therapeutics' latest filing, its Change in Acquisitions & Divestments stood at $34.0 million for Q3 2025, which was down 3928.57% from $76.2 million recorded in Q2 2025.
  • Over the past 5 years, TScan Therapeutics' Change in Acquisitions & Divestments peaked at $76.2 million during Q2 2025, and registered a low of $15.5 million during Q2 2024.